{"id":"antiretroviral-combinations","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":{"chemblId":"CHEMBL3990026","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Combination antiretroviral therapy (cART) typically includes nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, or entry inhibitors that act synergistically. By blocking HIV replication at multiple points in the viral lifecycle, combination therapy achieves sustained viral suppression, restores immune function, and reduces the emergence of drug-resistant viral strains.","oneSentence":"Antiretroviral combinations work by simultaneously targeting multiple steps of HIV replication through different drug classes to suppress viral load and prevent resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:01.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment and/or prevention)"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07219862","phase":"NA","title":"Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization","status":"NOT_YET_RECRUITING","sponsor":"Keck School of Medicine of USC","startDate":"2028-09-01","conditions":"HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active","enrollment":250},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT02656511","phase":"PHASE4","title":"Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2015-12","conditions":"HIV","enrollment":74},{"nctId":"NCT03304717","phase":"PHASE1, PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":"Aicardi Goutières Syndrome","enrollment":""},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT03205696","phase":"","title":"Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-08-01","conditions":"Human Immunodeficiency Virus","enrollment":101},{"nctId":"NCT02815566","phase":"PHASE4","title":"Bone Health in Aging HIV Infected Women","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2017-09-12","conditions":"Osteoporosis, HIV, Menopause","enrollment":34},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT05592613","phase":"PHASE3","title":"Next Generation Ingestible Sensors for Medication Adherence Measurement","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-02-06","conditions":"HIV Infection, Adherence, Medication, Adherence, Treatment","enrollment":15},{"nctId":"NCT02429791","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-14","conditions":"HIV Infections","enrollment":510},{"nctId":"NCT02422797","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-21","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT06507059","phase":"PHASE3","title":"Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-07-19","conditions":"HIV-1-infection, Non-Adherence, Medication","enrollment":40},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT02074891","phase":"","title":"Sustainable Healthcenter Implementation PrEP Pilot Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"HIV Chemoprophylaxis, HIV Preexposure Prophylaxis","enrollment":1420},{"nctId":"NCT04549467","phase":"PHASE4","title":"Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test","status":"COMPLETED","sponsor":"Fundacion IDEAA","startDate":"2020-11-17","conditions":"Hiv, HIV-1-infection","enrollment":244},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT00885664","phase":"PHASE4","title":"Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2005-10","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT01650558","phase":"NA","title":"Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-11","conditions":"HIV","enrollment":1499},{"nctId":"NCT03113123","phase":"NA","title":"Prevention of HIV in \"Île-de-France\"","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-05-03","conditions":"HIV Infections","enrollment":3257},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":"Bone Demineralization","enrollment":53},{"nctId":"NCT04318210","phase":"NA","title":"Open Label Extension (OLE) of the TDF2 Study, Botswana","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-10","conditions":"HIV Infections","enrollment":229},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT03296553","phase":"PHASE2","title":"Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2015-10-01","conditions":"Kaposi Sarcoma, Human Immunodeficiency Virus, Immune Reconstitution Syndrome","enrollment":40},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00000872","phase":"PHASE2","title":"Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00001091","phase":"PHASE1","title":"Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00076791","phase":"PHASE1","title":"Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"HIV Infections","enrollment":66},{"nctId":"NCT00006291","phase":"PHASE2","title":"Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT04385719","phase":"PHASE2","title":"Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2021-05-05","conditions":"Ebola, HIV/AIDS","enrollment":24},{"nctId":"NCT03976752","phase":"PHASE1","title":"Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-03-13","conditions":"HIV/AIDS","enrollment":41},{"nctId":"NCT04965662","phase":"PHASE4","title":"The Role of Home Packs of HIV PEPSE in High Risk Individuals","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2018-01-01","conditions":"HIV-1-infection","enrollment":139},{"nctId":"NCT04050371","phase":"PHASE4","title":"Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-08-03","conditions":"HIV Prevention, Transgender Health","enrollment":48},{"nctId":"NCT02870790","phase":"PHASE3","title":"Expanded PrEP Implementation in Communities in NSW","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-03","conditions":"HIV, STI","enrollment":9733},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT04658329","phase":"","title":"Cohorte Nationale VIH-2","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"1994-01-01","conditions":"HIV-2 Infection","enrollment":1185},{"nctId":"NCT02600819","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-14","conditions":"HIV-1 Infection","enrollment":55},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT03472963","phase":"PHASE1","title":"Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-04-27","conditions":"HIV Infections","enrollment":35},{"nctId":"NCT04531072","phase":"PHASE4","title":"Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine","status":"COMPLETED","sponsor":"Fogarty International Center of the National Institute of Health","startDate":"2018-09-18","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01797445","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-12","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT00448669","phase":"PHASE2, PHASE3","title":"Botswana TDF/FTC Oral HIV Prophylaxis Trial","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2007-03","conditions":"HIV Infections","enrollment":1219},{"nctId":"NCT02206555","phase":"PHASE4","title":"PrEP Demonstration Project (PRELUDE Study)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2014-11-14","conditions":"HIV","enrollment":327},{"nctId":"NCT03218592","phase":"PHASE4","title":"ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-06-28","conditions":"HIV/AIDS","enrollment":36},{"nctId":"NCT01352117","phase":"PHASE3","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11-18","conditions":"HIV-1 Infection, Kaposi's Sarcoma","enrollment":192},{"nctId":"NCT04132674","phase":"PHASE4","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed","status":"UNKNOWN","sponsor":"Vancouver Infectious Diseases Centre","startDate":"2018-11-26","conditions":"Human Immunodeficiency Virus I Infection, Drug Use","enrollment":40},{"nctId":"NCT03087890","phase":"PHASE4","title":"Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2017-03-30","conditions":"HIV-1-infection, Pneumocystis Pneumonia, Opportunistic Infections","enrollment":537},{"nctId":"NCT03049176","phase":"","title":"The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-03-13","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT01229761","phase":"PHASE2","title":"Study to Improve Survival Among HIV-Exposed Infants in Botswana","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2011-05","conditions":"HIV Infections, Neutropenia, Anemia","enrollment":3724},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT01632345","phase":"PHASE2","title":"A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-12","conditions":"HIV Infections","enrollment":342},{"nctId":"NCT03877536","phase":"NA","title":"Antiretroviral Therapy for Acute HIV Infection","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2019-03-17","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01497899","phase":"PHASE2","title":"Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12-28","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":279},{"nctId":"NCT01780506","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-26","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT01968551","phase":"PHASE3","title":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-03","conditions":"HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":158},{"nctId":"NCT01967940","phase":"PHASE3","title":"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-25","conditions":"HIV, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":55},{"nctId":"NCT02707601","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-01","conditions":"HIV-1 Infection, HCV Infection","enrollment":150},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01902186","phase":"PHASE4","title":"Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2014-09","conditions":"HIV Infection, Osteopenia","enrollment":4},{"nctId":"NCT00442962","phase":"PHASE4","title":"HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2007-05","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00090779","phase":"PHASE2","title":"Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-01","conditions":"HIV Infections","enrollment":130},{"nctId":"NCT00632970","phase":"PHASE4","title":"Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals","status":"TERMINATED","sponsor":"George Washington University","startDate":"2008-02","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT01721109","phase":"PHASE2, PHASE3","title":"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":50},{"nctId":"NCT02770508","phase":"PHASE4","title":"Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2015-11","conditions":"HIV-1 Infection","enrollment":145},{"nctId":"NCT02180438","phase":"PHASE4","title":"An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-09","conditions":"HIV-2 Infection","enrollment":30},{"nctId":"NCT01450189","phase":"NA","title":"A Key Link for Transmission Prevention","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-10","conditions":"HIV","enrollment":46},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":139,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cART"],"phase":"phase_3","status":"active","brandName":"Antiretroviral Combinations","genericName":"Antiretroviral Combinations","companyName":"Chang Gung Memorial Hospital","companyId":"chang-gung-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiretroviral combinations work by simultaneously targeting multiple steps of HIV replication through different drug classes to suppress viral load and prevent resistance. Used for HIV-1 infection (treatment and/or prevention).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}